## Michael Frumovitz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2782716/publications.pdf

Version: 2024-02-01

144 papers 8,098 citations

45 h-index 85 g-index

149 all docs 149 docs citations

times ranked

149

6974 citing authors

#	Article	IF	CITATIONS
1	Definitive pelvic radiation therapy improves survival in stage IVB neuroendocrine cervical carcinoma: A NeCTuR study. Gynecologic Oncology, 2022, 165, 530-537.	0.6	5
2	Lymphatic Mapping and Sentinel Node Biopsy in High-Grade Uterine Cancers. Current Oncology Reports, 2022, 24, 1521-1529.	1.8	4
3	A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. Supportive Care in Cancer, 2021, 29, 213-222.	1.0	2
4	Fertility considerations prior to conservative management of gynecologic cancers. International Journal of Gynecological Cancer, 2021, 31, 339-344.	1.2	8
5	Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study. International Journal of Gynecological Cancer, 2021, 31, 495-501.	1.2	9
6	Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer. International Journal of Gynecological Cancer, 2021, 31, 647-655.	1.2	28
7	An Integrated Approach to Selecting a Prepared Medical Decision-Maker. Journal of Pain and Symptom Management, 2021, 61, 1305-1310.	0.6	2
8	Comparison of Internal Patient Satisfaction Scores at a Cancer Center With Star Ratings on Online Physician-Rating Websites. JCO Oncology Practice, 2021, 17, e1181-e1188.	1.4	2
9	Early-stage, high-grade neuroendocrine cervical carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1179-1183.	1.2	O
10	ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 1317-1325.	1.2	79
11	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical Cancer Research, 2021, 27, 6354-6365.	3.2	31
12	Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2020, 222, 249.e1-249.e10.	0.7	78
13	Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecologic Oncology, 2020, 157, 161-166.	0.6	106
14	Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital charges. International Journal of Gynecological Cancer, 2020, 30, 352-357.	1.2	8
15	PARP and PD-L1 as Potential Therapeutic Targets for Women with Neuroendocrine Cervical Cancer. Gynecologic Oncology, 2020, 156, e21-e22.	0.6	2
16	Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. International Journal of Gynecological Cancer, 2020, 30, 1303-1307.	1.2	26
17	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. Journal of Cancer Education, 2020, , 1.	0.6	1
18	Coronavirus ( <scp>COVID</scp> â€19): Patient experience—Administrative services on the frontline during crisis. Head and Neck, 2020, 42, 1477-1481.	0.9	6

#	Article	IF	Citations
19	Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2020, 21, 851-860.	5.1	57
20	Successful pregnancy following chemotherapy in a survivor of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): A case report and review of literature. Gynecologic Oncology Reports, 2020, 32, 100576.	0.3	2
21	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecologic Oncology, 2020, 158, 570-575.	0.6	43
22	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. PLoS ONE, 2020, 15, e0234505.	1.1	25
23	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer. JAMA Oncology, 2020, 6, 1019.	3.4	124
24	Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecologic Oncology Reports, 2020, 31, 100532.	0.3	9
25	Phase 2 study of pembrolizumab in patients with advanced rare cancers., 2020, 8, e000347.		95
26	Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. International Journal of Gynecological Cancer, 2020, 30, 873-878.	1.2	42
27	COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. International Journal of Gynecological Cancer, 2020, 30, 561-563.	1.2	137
28	IGCS Intraoperative Technology Taskforce. Update on near infrared imaging technology: beyond white light and the naked eye, indocyanine green and near infrared technology in the treatment of gynecologic cancers. International Journal of Gynecological Cancer, 2020, 30, 670-683.	1.2	18
29	Encouraging worldwide adoption of sentinel lymph node biopsies for gynecologic malignancies. International Journal of Gynecological Cancer, 2020, 30, 281-282.	1.2	1
30	Surgical staging, the meaning of life, and other existential ponderings. International Journal of Gynecological Cancer, 2020, 30, 1862-1863.	1.2	4
31	Comparative genomics of high grade neuroendocrine carcinoma of the cervix., 2020, 15, e0234505.		0
32	Comparative genomics of high grade neuroendocrine carcinoma of the cervix., 2020, 15, e0234505.		0
33	Comparative genomics of high grade neuroendocrine carcinoma of the cervix., 2020, 15, e0234505.		0
34	Comparative genomics of high grade neuroendocrine carcinoma of the cervix., 2020, 15, e0234505.		0
35	Impact of Sentinel Node Approach in Gynecologic Cancer on Training Needs. Journal of Minimally Invasive Gynecology, 2019, 26, 727-732.	0.3	6
36	Updates and management algorithm for neuroendocrine tumors of the uterine cervix. International Journal of Gynecological Cancer, 2019, 29, 986-995.	1.2	71

3

#	Article	IF	Citations
37	Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed highâ€risk endometrial cancer: A prospective study. Cancer, 2019, 125, 3347-3353.	2.0	12
38	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget, 2019, 10, 3533-3546.	0.8	19
39	Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer. Journal of Gynecologic Oncology, 2019, 30, e45.	1.0	37
40	Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma. Obstetrics and Gynecology, 2019, 134, 1253-1259.	1.2	19
41	Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases. Gynecologic Oncology, 2019, 152, 101-105.	0.6	18
42	<i>PRKRA</i> /PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	1.9	23
43	Accuracy of Intraoperative Frozen Section Diagnosis of Borderline Ovarian Tumors by Hospital Type. Journal of Minimally Invasive Gynecology, 2019, 26, 87-93.	0.3	18
44	Radical parametrectomy after â€~cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete. Gynecologic Oncology, 2018, 149, 520-524.	0.6	7
45	Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. Gynecologic Oncology, 2018, 148, 474-479.	0.6	24
46	Radical Hysterectomy and Age: Outcomes Comparison Based on a Minimally Invasive vs an Open Approach. Journal of Minimally Invasive Gynecology, 2018, 25, 1224-1230.	0.3	16
47	Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecologic Oncology, 2018, 148, 132-138.	0.6	53
48	Tailoring adjuvant treatment in patients with uterine cancer – Authors' reply. Lancet Oncology, The, 2018, 19, e656.	5.1	1
49	The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. Journal of Gynecologic Oncology, 2018, 29, e68.	1.0	9
50	Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Frontiers in Immunology, 2018, 9, 2102.	2.2	33
51	Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. New England Journal of Medicine, 2018, 379, 1895-1904.	13.9	1,274
52	Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (≥2â€⁻cm) cervical cancer: Bridging the gap to fetal viability. Gynecologic Oncology, 2018, 150, 50-55.	0.6	10
53	Imaging and staging of neuroendocrine cervical cancer. Abdominal Radiology, 2018, 43, 3468-3478.	1.0	16
54	Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncology, The, 2018, 19, 1394-1403.	5.1	229

#	Article	IF	CITATIONS
55	Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer. Gynecologic Oncology, 2017, 145, 96-101.	0.6	143
56	Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF). Gynecologic Oncology, 2017, 146, 676-677.	0.6	8
57	A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecologic Oncology, 2017, 146, 234-239.	0.6	171
58	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clinical Cancer Research, 2017, 23, 2093-2104.	3.2	48
59	Sentinel Lymph Node Biopsy for Cervical Cancer Patients – What's It Gonna Take?. Gynecologic Oncology, 2017, 144, 3-4.	0.6	6
60	Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 546-553.	0.4	48
61	Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecologic Oncology, 2017, 144, 46-50.	0.6	49
62	Mucinous Carcinoma of the Ovary. , 2017, , 221-232.		0
63	Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecologic Oncology, 2016, 141, 588-591.	0.6	53
64	Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecologic Oncology, 2016, 143, 552-557.	0.6	35
65	Utility of indocyanine green (ICG) intra-operative angiography to determine uterine vascular perfusion at the time of radical trachelectomy. Gynecologic Oncology, 2016, 143, 357-361.	0.6	25
66	Feasibility of a reduced fieldâ€ofâ€view diffusionâ€weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer. Journal of Magnetic Resonance Imaging, 2016, 43, 316-324.	1.9	27
67	Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer. Gynecologic Oncology, 2016, 142, 283-285.	0.6	11
68	Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?. Journal of Minimally Invasive Gynecology, 2016, 23, 186-193.	0.3	47
69	<i>Is it equivalent?</i> Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment. Journal of Oncology Pharmacy Practice, 2016, 22, 599-604.	0.5	31
70	Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology. International Journal of Gynecological Cancer, 2015, 25, 1121-1127.	1.2	117
71	Make New Friends But Keep the Old: Minimally Invasive Surgery Training in Gynecologic Oncology Fellowship Programs. International Journal of Gynecological Cancer, 2015, 25, 1115-1120.	1.2	12
72	Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. Gynecologic Oncology, 2015, 136, 48-53.	0.6	79

#	Article	IF	CITATIONS
73	Sentinel Nodes in Cervical Cancer: Surgical Innovation Outside the Ivory Towers. Annals of Surgical Oncology, 2015, 22, 1759-1760.	0.7	2
74	Laparoscopic Supracervical Hysterectomy With Morcellation: Should It Stay or Should It Go?. Journal of Minimally Invasive Gynecology, 2015, 22, 185-192.	0.3	20
75	Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?. Gynecologic Oncology, 2015, 136, 269-273.	0.6	21
76	Radical trachelectomy in early-stage cervical cancer: A comparison of laparotomy and minimally invasive surgery. Gynecologic Oncology, 2015, 138, 585-589.	0.6	86
77	Challenges in the diagnosis and management of cervical neuroendocrine carcinoma. Expert Review of Anticancer Therapy, 2015, 15, 805-810.	1.1	42
78	Overview of the Role of Imaging in Pelvic Exenteration. Radiographics, 2015, 35, 1286-1294.	1.4	13
79	Preventing Complications in Minimally Invasive Gynecologic Surgery. Current Obstetrics and Gynecology Reports, 2015, 4, 176-180.	0.3	1
80	Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation. Gynecologic Oncology Reports, 2014, 10, 28-29.	0.3	38
81	Patient Preferences for Side Effects Associated With Cervical Cancer Treatment. International Journal of Gynecological Cancer, 2014, 24, 1077-1084.	1.2	15
82	Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecologic Oncology, 2014, 135, 451-454.	0.6	37
83	Morbid Obesity as an Independent Risk Factor for Disease-Specific Mortality in Women With Cervical Cancer. Obstetrics and Gynecology, 2014, 124, 1098-1104.	1.2	43
84	A case for caution in the pursuit of the sentinel node in women with endometrial carcinoma. Gynecologic Oncology, 2014, 132, 275-279.	0.6	25
85	Lymphadenectomy in Locally Advanced Cervical Cancer Study (LiLACS): Phase III Clinical Trial Comparing Surgical With Radiologic Staging in Patients With Stages IB2–IVA Cervical Cancer. Journal of Minimally Invasive Gynecology, 2014, 21, 3-8.	0.3	<b>7</b> 3
86	Mucinous Tumors of the Ovary: Current Thoughts on Diagnosis and Management. Current Oncology Reports, 2014, 16, 389.	1.8	133
87	Management of low-risk early-stage cervical cancer: Should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?. Gynecologic Oncology, 2014, 132, 254-259.	0.6	172
88	A comparison of extraperitoneal versus transperitoneal laparoscopic or robotic para-aortic lymphadenectomy for staging of endometrial carcinoma. Gynecologic Oncology, 2014, 132, 366-371.	0.6	56
89	Sentinel Lymph Node Evaluation in Women with Cervical Cancer. Journal of Minimally Invasive Gynecology, 2014, 21, 540-545.	0.3	47
90	Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: A feasibility study. Gynecologic Oncology, 2014, 132, 149-153.	0.6	35

#	Article	IF	CITATIONS
91	Successful Laparoscopic Removal of Adnexal Mass in a Patient With a Large Ventral Hernia. Journal of Minimally Invasive Gynecology, 2014, 21, 325-326.	0.3	1
92	Physician pain and discomfort during minimally invasive gynecologic cancer surgery. Gynecologic Oncology, 2014, 134, 243-247.	0.6	45
93	Pelvic exenteration: Impact of age on surgical and oncologic outcomes. Gynecologic Oncology, 2014, 132, 114-118.	0.6	27
94	Analgesic and Antiemetic Requirements After Minimally Invasive Surgery for Early Cervical Cancer: A Comparison Between Laparoscopy and Robotic Surgery. Annals of Surgical Oncology, 2013, 20, 1355-1359.	0.7	33
95	Targeting Src and Tubulin in Mucinous Ovarian Carcinoma. Clinical Cancer Research, 2013, 19, 6532-6543.	3.2	38
96	Unverifiable Accomplishments and Publications on Applications for Gynecologic Oncology Fellowships. Obstetrics and Gynecology, 2012, 119, 504-508.	1.2	7
97	Anatomic Location of PET-Positive Aortocaval Nodes in Patients with Locally Advanced Cervical Cancer: Implications for Surgical Staging. International Journal of Gynecological Cancer, 2012, 22, 1203-1207.	1.2	8
98	Utility of conization with frozen section for intraoperative triage prior to definitive hysterectomy. Gynecologic Oncology, 2012, 127, 307-311.	0.6	7
99	"Triple injection―lymphatic mapping technique to determine if parametrial nodes are the true sentinel lymph nodes in women with cervical cancer. Gynecologic Oncology, 2012, 127, 467-471.	0.6	25
100	Metastatic adenocarcinoma found in inguinal, pelvic and para-aortic lymph nodes 14years following hysterectomy for adenocarcinoma in situ of the cervix. Gynecologic Oncology Case Reports, 2012, 2, 97-99.	0.9	2
101	Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecologic Oncology, 2012, 125, 241-244.	0.6	11
102	Quality of laparoscopic radical hysterectomy in developing countries: A comparison of surgical and oncologic outcomes between a comprehensive cancer center in the United States and a cancer center in Colombia. Gynecologic Oncology, 2012, 125, 326-329.	0.6	14
103	Conservative management of early stage cervical cancer: Is there a role for less radical surgery?. Gynecologic Oncology, 2011, 120, 321-325.	0.6	117
104	Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecologic Oncology, 2011, 123, 333-336.	0.6	118
105	Balancing Fertility and Oncologic Outcomes: Can We Have Our Cake and Eat It Too?. Annals of Surgical Oncology, 2011, 18, 10-11.	0.7	1
106	Laparoscopic extraperitoneal paraâ€aortic lymphadenectomy in locally advanced cervical cancer1. Cancer, 2011, 117, 1928-1934.	2.0	161
107	Minimally Invasive Surgical Approaches for Patients With Endometrial Cancer. Clinical Obstetrics and Gynecology, 2011, 54, 226-234.	0.6	19
108	Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research, 2011, 17, 5367-5378.	3.2	42

#	Article	IF	CITATIONS
109	Primary Malignant Melanoma of the Vagina. Obstetrics and Gynecology, 2010, 116, 1358-1365.	1.2	105
110	Prevalence of Lymph Node Metastasis in Primary Mucinous Carcinoma of the Ovary. Obstetrics and Gynecology, 2010, 116, 269-273.	1.2	76
111	Microscopic Evaluation of Lymph-Node-Bearing Tissue in Early-Stage Cervical Cancer: A Dual-Institution Review. Annals of Surgical Oncology, 2010, 17, 1106-1110.	0.7	3
112	Unmasking the complexities of mucinous ovarian carcinoma. Gynecologic Oncology, 2010, 117, 491-496.	0.6	85
113	Conservative surgery in early-stage cervical cancer: What percentage of patients may be eligible for conization and lymphadenectomy?. Gynecologic Oncology, 2010, 119, 183-186.	0.6	34
114	Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer. Gynecologic Oncology, 2010, 119, 422-425.	0.6	28
115	Parametrial Involvement in Radical Hysterectomy Specimens for Women With Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2009, 114, 93-99.	1.2	174
116	Trends in laparoscopic and robotic surgery among gynecologic oncologists: A survey update. Gynecologic Oncology, 2009, 112, 501-505.	0.6	102
117	Sentinel Node Mapping in Vulvovaginal Melanoma Using SPECT/CT Lymphoscintigraphy. Clinical Nuclear Medicine, 2009, 34, 859-861.	0.7	37
118	Is Lymphatic Mapping in Uterine Cancer Feasible?. Annals of Surgical Oncology, 2008, 15, 1815-1817.	0.7	7
119	Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecologic Oncology, 2008, 108, 478-481.	0.6	58
120	Lymphatic mapping and sentinel lymph node detection in women with cervical cancer. Gynecologic Oncology, 2008, 110, S17-S20.	0.6	39
121	Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer. Gynecologic Oncology, 2008, 110, S21-S24.	0.6	51
122	Laparoscopy training in gynecologic oncology fellowship programs. Gynecologic Oncology, 2008, 111, 197-201.	0.6	17
123	A Phase III Randomized Clinical Trial Comparing Laparoscopic or Robotic Radical Hysterectomy with Abdominal Radical Hysterectomy in Patients with Early Stage Cervical Cancer. Journal of Minimally Invasive Gynecology, 2008, 15, 584-588.	0.3	144
124	Radical Hysterectomy in Obese and Morbidly Obese Women With Cervical Cancer. Obstetrics and Gynecology, 2008, 112, 899-905.	1.2	30
125	Ultrastaging Improves Detection of Metastases in Sentinel Lymph Nodes of Uterine Cervix Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2008, 32, 1336-1343.	2.1	70
126	Lymphatic mapping and sentinel node biopsy in vulvar, vaginal, and cervical cancers. Oncology, 2008, 22, 529-36; discussion 538-9, 542-3.	0.4	6

#	Article	IF	Citations
127	Comparison of Total Laparoscopic and Abdominal Radical Hysterectomy for Patients With Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2007, 110, 1174-1175.	1.2	4
128	Comparison of Total Laparoscopic and Abdominal Radical Hysterectomy for Patients With Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2007, 110, 96-102.	1.2	217
129	Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecologic Oncology, 2007, 104, 100-103.	0.6	118
130	Total laparoscopic radical hysterectomy: Surgical technique and instrumentation. Gynecologic Oncology, 2007, 104, 13-16.	0.6	15
131	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecologic Oncology, 2007, 104, 768-778.	0.6	64
132	Therapeutic value of pretherapeutic extraperitoneal laparoscopic staging of locally advanced cervical carcinoma. Gynecologic Oncology, 2007, 105, 304-311.	0.6	202
133	Current Perspectives on Lymphatic Mapping in Carcinomas of the Uterine Corpus and Cervix. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 471-478.	2.3	5
134	Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. American Journal of Obstetrics and Gynecology, 2006, 194, 1186-1193.	0.7	36
135	Electrothermal bipolar coagulation for pelvic exenterations. Gynecologic Oncology, 2006, 102, 534-536.	0.6	10
136	Fertility-sparing therapy for young women with endometrial cancer. Expert Review of Anticancer Therapy, 2006, 6, 27-32.	1.1	14
137	Lymphatic mapping and sentinel node detection in gynecologic malignancies of the lower genital tract. Current Oncology Reports, 2005, 7, 435-443.	1.8	11
138	Quality of Life and Sexual Functioning in Cervical Cancer Survivors. Journal of Clinical Oncology, 2005, 23, 7428-7436.	0.8	360
139	Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. Gynecologic Oncology, 2004, 92, 205-210.	0.6	31
140	Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. Gynecologic Oncology, 2004, 94, 746-753.	0.6	67
141	Hormonal therapy for the management of grade $1$ endometrial adenocarcinoma: a literature review. Gynecologic Oncology, 2004, 95, 133-138.	0.6	309
142	Predictors of final histology in patients with endometrial cancer. Gynecologic Oncology, 2004, 95, 463-468.	0.6	133
143	Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer1. Journal of the American College of Surgeons, 2004, 199, 388-393.	0.2	132
144	Impact of timing of urinary catheter removal on voiding dysfunction after radical hysterectomy for early cervical cancer. International Journal of Gynecological Cancer, 0, , ijgc-2022-003654.	1.2	1